EXTON, Pa.--(BUSINESS WIRE)--Aug 13, 2014--DSM, a global leader in materials science and regenerative medicine, announced today the launch of its cellular therapy development services. Cellular therapies use a patient’s own cells to improve healing of an injury or disease. DSM develops products that are distributed by major biotechnology and medical device companies into the hands of qualified physicians, who are ultimately responsible for patient care. DSM’s expertise lies in the isolation and concentration of autologous cells at the point of care, along with the technologies to deliver these cells independently or in concert with a variety of other biomaterials to enhance therapeutic effect. DSM offers a complete package of design, development and manufacturing services to create cellular therapy products that are clinically valuable and commercially viable.
The first product, developed by DSM and launched by DePuy Synthes Mitek Sports Medicine, concentrates platelets from whole blood in only two and a half minutes. The DePuy Synthes Mitek Sports Medicine PEAK™ Platelet Rich Plasma System yields a higher concentration of undamaged platelets and a more consistent output than existing devices on the market. Further, the device weighs only four pounds, making it easy to store in surgical specialty rooms as well as transport through a doctor’s office or hospital.
“DSM is in a position to help unleash the potential of autologous cellular therapies,” said Chad Smith, Director of Mechanical Devices at DSM Biomedical. “The emerging and fragmented field has been hamstrung by products that are difficult to use, time consuming, and inconsistent. Our distribution agreement with DePuy Synthes Mitek Sports Medicine signals the first step towards greater physician confidence in their tools.DSM looks forward to partnerships with major companies who seek to add cellular therapy devices to their portfolio.”